Spago Nanomedical AB (SPAGO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.201x

Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has a cash flow conversion efficiency ratio of -0.201x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.19 Million ≈ $-665.71K USD) by net assets (Skr30.75 Million ≈ $3.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Spago Nanomedical AB - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Spago Nanomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SPAGO liabilities breakdown for a breakdown of total debt and financial obligations.

Spago Nanomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Spago Nanomedical AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Ace Digital AS
OL:ACED
N/A
National Plastic Co Ltd Preferred
KO:004255
0.027x
GENINCODE PLC LS -01
F:9PL
N/A
Media Lab SpA
PA:MLLAB
N/A
Truscreen Group Ltd
AU:TRU
-0.502x
Sky Quarry Inc
NASDAQ:SKYQ
-0.229x
Ho Hup Construction Company
KLSE:5169
0.004x
Noble Mineral Exploration Inc
V:NOB
-0.094x

Annual Cash Flow Conversion Efficiency for Spago Nanomedical AB (2011–2025)

The table below shows the annual cash flow conversion efficiency of Spago Nanomedical AB from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see SPAGO company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr30.75 Million
≈ $3.31 Million
Skr-28.30 Million
≈ $-3.05 Million
-0.920x +11.77%
2024-12-31 Skr33.23 Million
≈ $3.58 Million
Skr-34.67 Million
≈ $-3.73 Million
-1.043x +4.03%
2023-12-31 Skr41.32 Million
≈ $4.45 Million
Skr-44.91 Million
≈ $-4.83 Million
-1.087x -461.18%
2022-12-31 Skr197.16 Million
≈ $21.22 Million
Skr-38.19 Million
≈ $-4.11 Million
-0.194x -0.64%
2021-12-31 Skr184.81 Million
≈ $19.89 Million
Skr-35.57 Million
≈ $-3.83 Million
-0.192x -63.76%
2020-12-31 Skr159.67 Million
≈ $17.18 Million
Skr-18.77 Million
≈ $-2.02 Million
-0.118x +24.02%
2019-12-31 Skr137.63 Million
≈ $14.81 Million
Skr-21.29 Million
≈ $-2.29 Million
-0.155x -79.87%
2018-12-31 Skr122.22 Million
≈ $13.15 Million
Skr-10.51 Million
≈ $-1.13 Million
-0.086x -19.90%
2017-12-31 Skr107.78 Million
≈ $11.60 Million
Skr-7.73 Million
≈ $-831.87K
-0.072x +34.47%
2016-12-31 Skr71.84 Million
≈ $7.73 Million
Skr-7.86 Million
≈ $-846.18K
-0.109x -33.92%
2015-12-31 Skr65.41 Million
≈ $7.04 Million
Skr-5.34 Million
≈ $-575.21K
-0.082x +23.04%
2014-12-31 Skr56.05 Million
≈ $6.03 Million
Skr-5.95 Million
≈ $-640.53K
-0.106x +47.60%
2013-12-31 Skr38.18 Million
≈ $4.11 Million
Skr-7.74 Million
≈ $-832.62K
-0.203x -1324.77%
2012-12-31 Skr42.25 Million
≈ $4.55 Million
Skr-601.00K
≈ $-64.68K
-0.014x +33.80%
2011-12-31 Skr12.84 Million
≈ $1.38 Million
Skr-276.00K
≈ $-29.70K
-0.021x --

About Spago Nanomedical AB

ST:SPAGO Sweden Biotechnology
Market Cap
$8.47 Million
Skr78.73 Million SEK
Market Cap Rank
#27272 Global
#600 in Sweden
Share Price
Skr0.12
Change (1 day)
+5.78%
52-Week Range
Skr0.09 - Skr0.40
All Time High
Skr19.04
About

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more